Non-invasive MRI Test for Scarring in the Liver
Tests a 4D-MRI scan to stage liver scarring in adults with liver disease.
Plain-language title generated from the registry record
Registry title: Identification of Hepatic Fibrosis Using 4D-MRI
Key facts
- Where
- Basel and Liestal, SwitzerlandSee the 2 sites
Where in Switzerland
- University Hospital BaselBasel, SwitzerlandTaking people
- Kantonsspital Baselland (KSL)Liestal, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT05385237
- Record updated
- 18 March 2025
- Original description
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. 4D-MRI allows to overcome the limitations of currently used techniques. Hence, 4D-MRI may help to identify a novel biomarker for non-invasive staging of liver fibrosis , and therefore improve the final diagnosis of patients suffering from liver diseases.Read full original descriptionShow less
Noninvasive Stage Identification of Hepatic Fibrosis Using 4D-MRI
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. 4D-MRI allows to overcome the limitations of currently used techniques. Hence, 4D-MRI may help to identify a novel biomarker for non-invasive staging of liver fibrosis , and therefore improve the final diagnosis of patients suffering from liver diseases.
Inclusion: age ≥ 18 years; (a) Patients with histologically confirmed chronic liver disease, including NAFLD, ALD, viral hepatitis B and C, genetic (e.g. Wilson disease, hemochromatosis) or autoimmune liver disease; (b) Patients with acute liver inflammation or cardiac blood congestion to the liver (as assessed by laboratory values, imaging findings and clinical history); ability to understand and consent to participate in this study.
Exclusion: Medical implant like cardiac pacemaker, pump, hip prosthesis; Persons who have undergone brain or cardiac surgery; (a) Active hepatocellular carcinoma (HCC) (remark: patients with a history of HCC and curative treatment can be included); (c) Metabolic syndrome, BMI >30 kg/m2; (c) Acute or chronic liver disease; Metallic objects in the body (e.g. splinters after an accident); Claustrophobia; Body Weight >140kg or as provided by the MR manufacturer; Pregnant and lactating women; (a) CHILD C cirrhosis; (a) and (b) Patients with overt ascites (except if they respond to diuretic treatment and the ascites resolves); Patients not willing or able to give a written informed consent.